Article3 Biotech2025
Enhanced therapeutic approach for vaginal candidiasis: chitosan nanoparticulate thermoreversible in situ gels for sustained clotrimazole delivery.
Article in 3 Biotech, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to develop and evaluate clotrimazole (CLZ)-loaded chitosan (CS) nanoparticles in a thermoreversible in situ gel for treating vaginal candidiasis (VC). Chitosan nanoparticles (CS-NPs) were prepared using ionotropic gelation with optimization through the design of experiments (DoE), considering factors such as chitosan pH, sodium tripolyphosphate (TPP) pH, the ratio of chitosan to TPP, and drug. Under optimal conditions (pH of CS, TPP, CS: TPP, and drug at 2, 2, 4:1, and 10 mg), nanoparticles exhibited desirable properties: particle size of 101.7 nm, polydispersity index (PDI) of 0.108, zeta potential of 35.4, and encapsulation efficiency of 98.36%. Thermoreversible in situ gels incorporating poloxamer (PXM) 407 and 188 were produced via the cold method and evaluated for mechanical and physicodynamic properties. It was found that nanoparticulate thermoreversible gel (NTG) prepared with 24% PXM 407, 4% PXM 188, 0.5% HPMC E-50, or 0.5% chitosan is suitable for vaginal administration, since it fulfills the in situ gel characteristics such as pH (4.7), gelation temperature and time (36 ℃ ± 0.2 and 4 ± 0.2 min), and viscosity (2690 cP (centipoise) at 25 ℃ and 15,600 cP at 37 ℃). In vitro release studies for the developed formulation showed 98% drug release over 72 h, with an extended residence time compared to the marketed formulation. In vitro antifungal and cytocompatibility studies revealed that the developed NTG was effective against VC and free from cytotoxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.